2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

Metabolic Dysfunction-Associated Steatotic Liver Disease

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Peptides

2

Natural
Products

Targets Recommended:
Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-P11274A
    Zenagamtide sodium

    Amycretin sodium; NN 9487 sodium

    		 Amylin Receptor Insulin Receptor GCGR Metabolic Disease
    Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
    Zenagamtide sodium
  • HY-N0732
    Jolkinolide B
    1 Publications Verification

    		 IAP Akt Caspase NF-κB TGF-beta/Smad JAK Bacterial Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
    Jolkinolide B
  • HY-P11274
    Zenagamtide

    Amycretin; NN 9487

    		 Amylin Receptor GCGR Insulin Receptor Metabolic Disease
    Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
    Zenagamtide
  • HY-161247
    5-HT2A antagonist 2

    		5-HT Receptor Metabolic Disease
    5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
    5-HT2A antagonist 2
  • HY-156065
    S217879

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related Metabolic Disease
    S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .
    S217879
  • HY-179278
    LXR agonist 4

    		LXR Cardiovascular Disease Metabolic Disease Endocrinology
    LXR agonist 4 is a selective LXR inverse agonist with IC50 values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and FXR. LXR agonist 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) .
    LXR agonist 4
  • HY-173599
    NUV-244

    		PNPLA3 Cancer
    NUV-244 is a PNPLA3 I148M degrader. NUV-244 reduces PNPLA3 I148M levels on lipid droplets via BFAR-mediated ubiquitin-proteasome degradation .
    NUV-244
  • HY-181564
    MGAT2-IN-7

    		Acyltransferase Metabolic Disease
    MGAT2-IN-7 is an orally active monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) .
    MGAT2-IN-7
  • HY-183723
    GAA-4OH

    		Dihydroceramide Desaturase 1 (DES1) Metabolic Disease
    GAA-4OH is a potent and irreversible dihydroceramide desaturase-1 (DES1) inhibitor with an IC50 of 0.6 μM and a Ki of 139.5 nM. GAA-4OH undergoes oxidation to form a reactive iminoquinone that covalently blocks DES1’s catalytic cavity, causing permanent enzyme inactivation. GAA-4OH modulates sphingolipid balance by reducing ceramide-to-dihydroceramide ratios in liver tissue. GAA-4OH improves liver steatosis, inflammation, fibrosis, and reduces pro-inflammatory and pro-fibrogenic gene expression. GAA-4OH can be used for the research of metabolic dysfunction-associated steatotic liver disease (MASLD) .
    GAA-4OH
  • HY-N0732R
    Jolkinolide B (Standard)

    		Reference Standards IAP Akt Caspase NF-κB TGF-beta/Smad JAK Bacterial Apoptosis Infection Inflammation/Immunology Cancer
    Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
    Jolkinolide B (Standard)
  • HY-181862
    SHK1112218

    		Mitochondrial Metabolism Metabolic Disease
    SHK1112218 is an orally active mitochondrial proton carrier with an EC50 of 0.48 μM. SHK1112218 restores proton transport and increases oxygen consumption rate. SHK1112218 can be used for the research of diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease .
    SHK1112218
  • HY-180921
    GS-1291269

    		Ketohexokinase Metabolic Disease Endocrinology
    GS-1291269 is a potent and neutral ketohexokinase (KHK) inhibitor, with IC50s of 0.38 and 2.1 nM against KHK-C and KHK-A, respectively. GS-1291269 demonstrates liver and kidney fructose-1-phosphate (F1P) reduction in a fructose challenge model in rats. GS-1291269 can be used for kidney disease and metabolic-dysfunction-associated steatotic liver disease (MASLD) research .
    GS-1291269
  • HY-182046
    HD202A

    		MNK PPAR Eukaryotic Initiation Factor (eIF) Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, and Kd values of 1.913 μM and 5.244 μM, respectively) that inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. HD202A effectively suppresses body weight gain, hepatic lipid accumulation and elevation of serum lipids, significantly improves glucose tolerance and insulin sensitivity of the organism, and ameliorates inflammatory features. With these comprehensive pharmacological activities, HD202A exhibits great application potential in studies of metabolic dysfunction-associated steatotic liver disease .
    HD202A

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: